Evolution in Biomarker Testing in CCA

Groundbreaking advancements in cholangiocarcinoma research, including targeted therapies, immunotherapy innovations, and promising early detection strategies, are highlighted in this issue.

Explore pivotal advancements in research, care strategies, and collaborative efforts shared at the 12th Annual Cholangiocarcinoma Foundation Conference, shaping the future of cholangiocarcinoma treatment.

The 2025 ASCO GI Cancers Symposium on biliary tract cancer (BTC) emphasized significant research findings, particularly the relevance of mutational subsets, the role of personalized medicine, and the impact of multidisciplinary therapies on enhancing outcomes for patients with BTC.

The 6th Annual CCA Summit featured presentations and discussions on novel therapies, surgical approaches, locoregional therapies, the use of ctDNA monitoring, treatment options for localized multifocal intrahepatic cholangiocarcinoma, the role of consolidative radiotherapy, and advancements in artificial intelligence for CCA.

We are highlighting several key areas of clinical research in this issue of CCA News. The role of radiation therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) has been established in single-arm phase 2 trials; however, there is a lack of randomized controlled data.

Editor-in-Chief Milind M. Javle, MD, highlights takeaways from the 2024 Cholangiocarcinoma (CCA) Foundation Annual Conference.

Editor-in-Chief Milind M. Javle, MD, highlights takeaways from the ASCO GI 2024 symposium, emphasizing the latest developments in biliary tract cancer.

The 5th annual CCA Summit, held October 19-21, 2023, in Scottsdale, AZ, was a very successful meeting by all measures and has gradually become one of the key scientific meetings in biliary tract cancers.

As we approach the fall season, it is wonderful to reflect on some of the amazing research presented this year, most recently at the ASCO 2023 annual meeting. One of the major highlights of ASCO this year included the results of HER2/neu-directed novel therapies in biliary cancer. Shubham Pant, MD, MBBS, from MD Anderson Cancer Center, presented the results of the HERIZON-1 clinical trial of the bispecific antibody zanidatamab in HER2/neu-expressing biliary cancers.